Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press29010.17650/1994-4098-2009-0-1-2-46-52PHARMACOTHERAPYГИНЕКОЛОГИЯ. ФАРМАКОТЕРАПИЯTAXOTERE: UPDATE (REVIEW OF REPORTS AT THE 31st ANNUAL SYMPOSIUM ON BREAST CANCER (San Antonio, USA)ТАКСОТЕР: НОВЫЕ ДАННЫЕ (ОБЗОР СООБЩЕНИЙ, ПРЕДСТАВЛЕННЫХ НА 31-М ЕЖЕГОДНОМ СИМПОЗИУМЕ ПО РАКУ МОЛОЧНОЙ ЖЕЛЕЗЫ В САН-АНТОНИО, США)SteninaM. B.СтенинаМ. Б.
Russian Federation
m.stenina@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowГУ РОНЦ им. Н.Н. Блохина РАМН, Москва010520091-2465201092014010920142009https://ojrs.abvpress.ru/ojrs/article/view/290

The paper considers the reports which were presented at the 31st Annual Symposium on Breast Cancer, held in San Antonio (USA) in December 2008 and concerned different aspects of the use of Taxotere in this disease.

В статье рассмотрены сообщения, представленные на 31-м ежегодном симпозиуме по раку молочной железы, проходившем в Сан-Антонио (США) в декабре 2008 г., и касающиеся различных аспектов использования Таксотера при этой патологии.

breast cancertherapyTaxotereрак молочной железытерапияТаксотер1. Swain S.M., Jeong J.-H., Geyer C.E. et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combi- nations of adjuvant therapy containing doxorubicin, docetaxel and cyclophos- phamide in women with operable, node- positive breast cancer. Oral presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 75.Swain S.M., Jeong J.-H., Geyer C.E. et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combi- nations of adjuvant therapy containing doxorubicin, docetaxel and cyclophos- phamide in women with operable, node- positive breast cancer. Oral presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 75.2. Ganz P., Land S.R., Geyer C.E. et al. NSABP B-30: definitive analysis of quali- ty of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combi- nations of adjuvant therapy containing doxorubicin, docetaxel and cyclophos- phamide in women with operable, node- positive breast cancer. Oral presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 76.Ganz P., Land S.R., Geyer C.E. et al. NSABP B-30: definitive analysis of quali- ty of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combi- nations of adjuvant therapy containing doxorubicin, docetaxel and cyclophos- phamide in women with operable, node- positive breast cancer. Oral presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 76.3. Eiermann W., Pienkowski T., Crown J. et al. BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophos- phamide followed by docetaxel (AC?T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Oral presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 77.Eiermann W., Pienkowski T., Crown J. et al. BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophos- phamide followed by docetaxel (AC?T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Oral presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 77.4. Nitz U., Huober J., Lisboa B. et al. Superiority of sequential docetaxel over standard FE100C in patients with inter- mediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc. Cancer Res 2008;69(2):82. Abstr 78.Nitz U., Huober J., Lisboa B. et al. Superiority of sequential docetaxel over standard FE100C in patients with inter- mediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc. Cancer Res 2008;69(2):82. Abstr 78.5. Nitz U., Huober J.B., Lisboa A. et al. Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to ECdocetaxel in patients with 1—3 pos- itive lymph nodes. J Clin Oncol 2008;26(15):10. Abstr 515.Nitz U., Huober J.B., Lisboa A. et al. Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to ECdocetaxel in patients with 1—3 pos- itive lymph nodes. J Clin Oncol 2008;26(15):10. Abstr 515.6. Watanabe T. et al. Phase III two by two factorial comparisons of doxorubicin and cyclophosphamide followed by a tax- ane vs a taxane alone and paclitaxel vs. docetaxel in operable node positive breast cancer — results of the first interim analysis of NSASBC02 trial. Poster pres- entation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 4103.Watanabe T. et al. Phase III two by two factorial comparisons of doxorubicin and cyclophosphamide followed by a tax- ane vs a taxane alone and paclitaxel vs. docetaxel in operable node positive breast cancer — results of the first interim analysis of NSASBC02 trial. Poster pres- entation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 4103.7. Von Minckwitz G., Kaufmann M., Kummel S. et al. Integrated meta-analy- sis on 6402 patients with early breast can- cer receiving neoadjuvant anthracycline- taxane +/- trastuzumab containing chemotherapy. Cancer Res 2008;69(2):82. Abstr 79.Von Minckwitz G., Kaufmann M., Kummel S. et al. Integrated meta-analy- sis on 6402 patients with early breast can- cer receiving neoadjuvant anthracycline- taxane +/- trastuzumab containing chemotherapy. Cancer Res 2008;69(2):82. Abstr 79.8. Miles D., Chan A., Romieu G. et al. Randomized, double-blind, placebo- controlled, phase III study of Bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008;26(18):1008. Abstr LBA011.Miles D., Chan A., Romieu G. et al. Randomized, double-blind, placebo- controlled, phase III study of Bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008;26(18):1008. Abstr LBA011.9. Fumoleau P., Greil R., Rayson D. et al. Bevacizumab (BV) maintenance therapy significantly delays disease pro- gression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]). Poster presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 903.Fumoleau P., Greil R., Rayson D. et al. Bevacizumab (BV) maintenance therapy significantly delays disease pro- gression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]). Poster presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 903.10. Chan A., Vanlemmens L., Conte P.F. et al. Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study. Poster presenta- tion at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 1027.Chan A., Vanlemmens L., Conte P.F. et al. Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study. Poster presenta- tion at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 1027.11. Wardley A., Lohrisch C., Joy A.A. et al. Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) bevacizumab (BV) in inop- erable locally recurrent (LR) or metastat- ic breast cancer (mBC). Poster presenta- tion at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 1035.Wardley A., Lohrisch C., Joy A.A. et al. Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) bevacizumab (BV) in inop- erable locally recurrent (LR) or metastat- ic breast cancer (mBC). Poster presenta- tion at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 1035.12. Cortes J., Pivot X., Schneeweiss A. et al. Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with doc- etaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study. Poster presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 1030.Cortes J., Pivot X., Schneeweiss A. et al. Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with doc- etaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study. Poster presentation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 1030.13. Dirix L.Y., Romieu G., Provencher L. et al. Safety of bevacizum- ab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. Poster presenta- tion at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 4116.Dirix L.Y., Romieu G., Provencher L. et al. Safety of bevacizum- ab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. Poster presenta- tion at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 4116.14. Yardley D.A. et al. Preliminary safety results: addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer. Poster pres- entation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 4107.Yardley D.A. et al. Preliminary safety results: addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer. Poster pres- entation at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA; 10—14 December, 2008. Abstr 4107.